A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: A randomized, double-blind, two-period crossover study in healthy volunteers

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 108-114

  Darwish, Mona ^a   Chang, Steven ^a   Hellriegel, Edward T ^a  

^a CEPHALON INC   (United States)

Author keywords

cyclobenzaprine; extended release; low back pain; muscle relaxant; neck pain; once daily; pharmacokinetics; skeletal muscle spasm

Indexed keywords

CYCLOBENZAPRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG TOLERABILITY; DYSMENORRHEA; ETHNIC GROUP; FEMALE; GLOSSODYNIA; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOLUNTEER; WEIGHT;

ADOLESCENT; ADULT; AMITRIPTYLINE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL; YOUNG ADULT;

EID: 60349120557     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.014     Document Type: Article

References (18)

1. Ehrlich G.E. Low back pain. Bull World Health Organ 81 (2003) 671-676
2. Browning R., Jackson J.L., and O'Malley P.G. Cyclobenzapnne and back pain: A meta-analysis. Arch Intern Med 161 (2001) 1613-1620
3. Chou R., Huffman L.H., and American Pain Society/American College of Physicians. Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 147 (2007) 505-514
4. van Tulder M.W., Koes B.W., and Bouter L.M. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine 22 (1997) 21282156
5. Winchell G.A., King J.D., Chavez-Eng C.M., et al. Cyclobenzapnne pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol 42 (2002) 61-69
6. Borenstein D.G., and Korn S. Efficacy of a low-dose regimen of cyclobenzapnne hydrochloride in acute skeletal muscle spasm: Results of two placebo-controlled trials. Clin Ther 25 (2003) 1056-1073
7. Nibbelink D.W., Strickland S.C., McLean L.F., and Gould A.L. Cyclobenzapnne, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Their 1 (1978) 409-424
8. Katz W.A., and Dube J. Cyclobenzapnne in the treatment of acute muscle spasm: Review of a decade of clinical experience. Clin Ther 10 (1988) 216-228
9. Commissiong J.W., Karoum F., Reiffenstein R.J., and Neff N.H. Cyclobenzapnne: A possible mechanism of action for its muscle relaxant effect. Can J Physiol Pharmacol 59 (1981) 37-44
10. Share N.N., and McFarlane C.S. Cyclobenzapnne: Novel centrally acting skeletal muscle relaxant. Neuropharmacology 14 (1975) 675-684
11. Amrix [package insert] (2007), Cephalon, Inc, Frazer, Pa
12. Weil A., Narayana A., Chang S.C., and Nalamachu S. Efficacy of cyclobenzapnne hydrochloride extended-release 15 mgand 30 mg once-daily for low back and neck pain associated with muscle spasms: A pooled analysis of two randomized, double-blind, parallel-group, placebo-controlled, multicenter studies. Pain Med. 9 (2008) 134-135 Abstract 206
13. Greenberg R.N. Overview of patient compliance with medication dosing: A literature review. Clin Ther 6 (1984) 592-599
14. Stang P., Suppapanaya N., Hogue S.L., et al. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther 14 (2007) 241-246
15. Ward A., Bozkaya D., Fleischmann J., et al. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: Comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin 23 (2007) 2333-2345
16. Darwish M., Hellriegel E.T., and Xie F. Single-dose pharmacokinetics of once-daily cyclobenzapnne extended release 30 mg versus cyclobenzapnne immediate release 10 mg three times daily in healthy young adults. A randomized, open-label, two-period crossover, single-centre study. Clin Drug Investig 28 (2008) 793-801
17. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/pdf/17c.pdf Accessed October 10, 2008
18. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1) (June 10, 1996)